钠葡萄糖协同转运体2（SGLT2）抑制剂与乳腺癌和膀胱癌风险的关注仍存争议，其对癌症死亡率的影响尚未确定。我们旨在评估SGLT2抑制剂与癌症结果风险之间的关联。我们在PubMed、Embase和CENTRAL上查找了到2022年6月20日的SGLT2抑制剂成人随机对照试验，最少需随访48周。研究员提取了研究层面的数据，并使用RoB 2.0工具评估了研究内部偏倚风险和GRADE评估证据质量。我们进行了荟萃分析，总结了癌症结果的相对风险（RR）。共选取了76个试验，涵盖116375名参与者。总体偏倚风险低。SGLT2抑制剂不会降低/增加总体癌症风险（RR，1.03；95％置信区间[CI]，0.96-1.10）和癌症死亡率（RR，0.99；95％CI，0.85-1.16）。SGLT2抑制剂可能导致乳腺癌（RR，1.01；95％CI 0.77-1.32）和膀胱癌（RR，0.93；95％CI 0.71-1.21）风险的差异很小或不存。试验序贯分析提供了充分的样本量，以避免错过替代结果。SGLT2抑制剂与癌症结果的风险无关，提供了关于先前的安全顾虑的可靠数据。版权所有©2023年。Elsevier B.V.出版。

Concerns regarding breast and bladder cancer risk with Sodium-glucose cotransporter-2 (SGLT2) inhibitors remain controversial and its effect on cancer mortality is unknown. We aim to evaluate the association between SGLT2 inhibitors and the risk of cancer outcomes.We searched PubMed, Embase and CENTRAL up to June 20th, 2022, for randomized controlled trials of SGLT2 inhibitors in adults, with a minimum follow-up of 48 weeks. Researchers extracted study-level data and assessed within-study risk of bias with the RoB 2.0 tool and quality of evidence with GRADE. We performed meta-analyses summarizing the relative risks (RRs) of cancer outcomes.Seventy-six trials encompassing 116375 participants were selected. Overall risk of bias was low. SGLT2 inhibitors did not reduce/increase the overall risk of cancer (RR, 1.03; 95% confidence interval [CI], 0.96-1.10) and cancer mortality (RR, 0.99; 95% CI, 0.85-1.16). SGLT2 inhibitors likely result in little to no difference in the risk of breast (RR, 1.01; 95% CI 0.77-1.32) and bladder cancers (RR, 0.93; 95% CI 0.71-1.21). Trial sequential analysis provided evidence that the sample size was sufficient to avoid missing alternative results.SGTL2 inhibitors are not associated with an increased risk of cancer outcomes, providing reassuring data regarding previous safety concerns.Copyright © 2023. Published by Elsevier B.V.